TrialLeukemia & lymphoma2017

A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma.

Jonathon B Cohen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.